Elecoglipron
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
AstraZeneca · Phase 1 · Active, not recruiting · Enrollment 48
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Group 1: Period 1 | n/r | n/r | n/r | n/r |
| Group 1: Period 2 | n/r | n/r | n/r | n/r |
| Group 1: Period 3 | n/r | n/r | n/r | n/r |
| Group 1: Period 4 | n/r | n/r | n/r | n/r |
| Group 1: Period 5 | n/r | n/r | n/r | n/r |
| Group 1: Period 6 | n/r | n/r | n/r | n/r |
| Group 2: Period 1 | n/r | n/r | n/r | n/r |
| Group 2: Period 2 | n/r | n/r | n/r | n/r |
| Group 2: Period 3 | n/r | n/r | n/r | n/r |
| Group 2: Period 4 | n/r | n/r | n/r | n/r |
| Group 2: Period 5 | n/r | n/r | n/r | n/r |
| Group 2: Period 6 | n/r | n/r | n/r | n/r |
| Group 2: Period 7 | n/r | n/r | n/r | n/r |
Not shown
- Group 1: Period 1: endpoint not reported
- Group 1: Period 2: endpoint not reported
- Group 1: Period 3: endpoint not reported
- Group 1: Period 4: endpoint not reported
- Group 1: Period 5: endpoint not reported
- Group 1: Period 6: endpoint not reported
- Group 2: Period 1: endpoint not reported
- Group 2: Period 2: endpoint not reported
- Group 2: Period 3: endpoint not reported
- Group 2: Period 4: endpoint not reported
- Group 2: Period 5: endpoint not reported
- Group 2: Period 6: endpoint not reported
- Group 2: Period 7: endpoint not reported